VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock Now Rated “Reduce” by Sell-Side Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned an average recommendation of “Reduce” from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $0.95.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC acquired a new stake in shares of VistaGen Therapeutics in the 2nd quarter valued at approximately $79,000. BlackRock Inc. acquired a new position in shares of VistaGen Therapeutics during the 2nd quarter worth about $78,000. Renaissance Technologies LLC raised its holdings in shares of VistaGen Therapeutics by 81.2% in the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after purchasing an additional 130,509 shares during the period. Seven Fleet Capital Management LP bought a new stake in shares of VistaGen Therapeutics in the 4th quarter valued at about $42,000. Finally, AdvisorShares Investments LLC raised its holdings in shares of VistaGen Therapeutics by 10.8% in the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock valued at $158,000 after purchasing an additional 26,922 shares during the period. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Stock Performance

Shares of VistaGen Therapeutics stock opened at $0.20 on Tuesday. The business’s 50 day simple moving average is $0.25 and its 200 day simple moving average is $0.41. VistaGen Therapeutics has a 52-week low of $0.19 and a 52-week high of $5.14. The firm has a market cap of $9.01 million, a PE ratio of -0.12 and a beta of 0.33.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. The company had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities research analysts predict that VistaGen Therapeutics will post -1.45 EPS for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions.